Search - tctmd.com

Displaying 1 - 13 of 13

Sort: Relevancy | Date

News Daily News

Andexanet Alfa Pulled From US Market

Todd Neale

December 22, 2025

News Daily News

Reduced Shock Efficacy With Some Boston Scientific Defibrillation Leads

Todd Neale

August 06, 2025

News Opinion Off Script

Evoque and Patisiran: A Tale of Two Regulatory Journeys

Sanjay Kaul, MD

March 29, 2024

News Daily News

FDA Safety Communication Updates Stance on Endologix AAA Grafts

L.A. McKeown

January 13, 2022

News Daily News

FDA Reminder: Yearly, Lifelong Surveillance Needed for Endologix AAA Grafts

L.A. McKeown

December 04, 2020

News Daily News

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

Michael O'Riordan

November 14, 2019

News Daily News

FDA Analysis Points to Higher Death Risk With Paclitaxel-Based Devices for PAD

L.A. McKeown

March 15, 2019

News Daily News

FDA Adds Boxed Warning About CV Risks to Gout Drug Febuxostat

Shelley Wood

February 22, 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for January 2019

Caitlin E. Cox

January 31, 2019

News Daily News

FDA Calls It Quits on Black-Box Warnings for Smoking Cessation Drugs

Shelley Wood

December 20, 2016

News Daily News

Un Panel Asesor de la FDA Recomienda por un Estrecho Margen una Indicación de Mortalidad por EAC para el Antidiabético Empagliflozina

Michael O'Riordan

June 30, 2016

News Daily News

FDA 顾问小组小范围建议使用糖尿病药物 empagliflozin 来改善 CVD 死亡率

Michael O'Riordan

June 30, 2016

News Daily News

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Michael O'Riordan

June 30, 2016

Advertisement

Andexanet Alfa Pulled From US Market

Reduced Shock Efficacy With Some Boston Scientific Defibrillation Leads

Evoque and Patisiran: A Tale of Two Regulatory Journeys

FDA Safety Communication Updates Stance on Endologix AAA Grafts

FDA Reminder: Yearly, Lifelong Surveillance Needed for Endologix AAA Grafts

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

FDA Analysis Points to Higher Death Risk With Paclitaxel-Based Devices for PAD

FDA Adds Boxed Warning About CV Risks to Gout Drug Febuxostat

TCTMD’s Top 10 Most Popular Stories for January 2019

FDA Calls It Quits on Black-Box Warnings for Smoking Cessation Drugs

Un Panel Asesor de la FDA Recomienda por un Estrecho Margen una Indicación de Mortalidad por EAC para el Antidiabético Empagliflozina

FDA 顾问小组小范围建议使用糖尿病药物 empagliflozin 来改善 CVD 死亡率

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content